Enantioselective analysis of citalopram and metabolites in adolescents

Therapeutic Drug Monitoring

Volumn 23, Issue 6, 2001, Pages 658-664

  Carlsson, B ^a   Olsson, G ^a   Reis, M ^a   Walinder J ^a   Nordin, C ^a   Lundmark, J ^a   Scordo, M G ^a   Dahl, M L ^a   Bengtsson, F ^a   Ahlner, J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Adolescent; Citalopram; Enantiomer; Genotypes

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DINORCITALOPRAM; DRUG METABOLITE; NORCITALOPRAM; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; STEREOISOMERISM;

EID: 0035179512     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200112000-00011     Document Type: Article

References (34)

1. A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants
2. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
3. Citalopram in the treatment of depression and other potential uses in psychiatry
4. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans
5. Pharmacology and pharmacokinetics of citalopram and other SSRIs
6. Steady-state pharmacokinetics of citalopram in young and elderly subjects
7. A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents
8. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience
9. Selective serotonin reuptake inhibitors in the treatment of pediatric anxiety disorders: A review
10. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms
11. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
12. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes
13. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
14. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
15. The pharmacological effect of citalopram residues in the (S)-(+)- enantiomer
16. Plasma levels of citalopram enantiomers and metabolites in elderly patients
17. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography
18. Stereoselective HPLC-assay for citalopram and its metabolites
19. Child and adolescent obsessive-compulsive disorder treated with citalopram: Findings from an open trial of 23 cases
20. Citalopram and fluvoxamine in Tourette's disorder
21. Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalopram and metabolites in plasma by high- performance liquid chromatography
22. Optimisation and characterisation of the chiral separation of citalopram and its demethylated metabolites by response surface methodology
23. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
24. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype
25. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
26. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
27. Identification of a new genetic defect responsible for the polymorphism of (S)mephenytoin metabolism in Japanese
28. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
29. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences
30. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers
31. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel
32. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver
33. Stereoselectivity of drug action
34. Pharmacological importance of stereochemical resolution of enantiomeric drugs